by Isogenica Webmaster | Nov 2025 | Blogs
Building Smarter Therapeutics with VHH Bolt-Ons Single-domain antibodies derived from camelids, also known as VHHs or nanobodies, are highly adaptable binding domains widely used in protein engineering. They were pioneered by Raymond Hamers at Vrije Universiteit...
by Isogenica Webmaster | Oct 2025 | Blogs
CIS Display™ vs. Phage Display: Choosing the Right Fit for VHH or Peptide Discovery Choosing the right display technology is a critical decision in therapeutic and diagnostic discovery procedures. This article compares CIS Display™ with Phage Display, focusing on...
by Isogenica Webmaster | Sep 2025 | Blogs
NGS in Antibody Discovery: How Deep is Your Sequence? Next-generation sequencing (NGS) has revolutionized antibody discovery by enabling high-depth analysis of diverse libraries, surpassing the limitations of traditional methods like Sanger sequencing. This article...
by Isogenica Webmaster | Jul 2025 | Blogs
Unlocking Hard-to-Drug Targets: How VHH Antibodies Overcome Drug Discovery Barriers For decades, certain drug targets have been labeled as “undruggable” due to their complex structures, lack of accessible binding sites, or dynamic conformational changes....
by Isogenica Webmaster | May 2025 | Blogs
A Competitive and Ethical Future in Discovery Pharmaceutical and biotech R&D is undergoing a notable shift in how therapeutic antibodies are discovered. Traditionally, antibody generation relied on immunizing animals (e.g. mice, rabbits, or even llamas) to raise...
by Isogenica Webmaster | May 2025 | Blogs
Isogenica named in Business Weekly’s Ones2Watch In Q1 2025, Business Weekly published its latest Killer50 showcase – a long-standing benchmark for innovation in UK life sciences Recognition in a Difficult Quarter In Q1 2025, Business Weekly...